CNTG Stock - Centogene N.V.
Unlock GoAI Insights for CNTG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $48.54M | $47.47M | $42.23M | $38.45M | $48.78M |
| Gross Profit | $17.25M | $19.92M | $14.57M | $3.17M | $22.77M |
| Gross Margin | 35.5% | 42.0% | 34.5% | 8.2% | 46.7% |
| Operating Income | $-29,659,000 | $-36,773,000 | $-55,488,000 | $-53,731,000 | $-19,338,000 |
| Net Income | $-35,532,000 | $-31,841,000 | $-46,246,000 | $-21,378,000 | $-20,855,000 |
| Net Margin | -73.2% | -67.1% | -109.5% | -55.6% | -42.8% |
| EPS | $-1.27 | $-1.11 | $-2.09 | $-1.02 | $-1.27 |
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Visit WebsiteEarnings History & Surprises
CNTGEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 21, 2024 | $-0.41 | $-0.10 | +75.6% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.44 | — | — | — |
Q1 2024 | Jan 18, 2024 | — | — | — | — |
Q3 2023 | Sep 7, 2023 | — | $-0.94 | — | — |
Q3 2023 | Jul 21, 2023 | $-0.41 | $-0.54 | -31.7% | ✗ MISS |
Q2 2023 | May 16, 2023 | $-0.40 | $-0.47 | -17.5% | ✗ MISS |
Q2 2023 | Apr 28, 2023 | $-0.40 | $-0.48 | -19.6% | ✗ MISS |
Q4 2022 | Dec 22, 2022 | $-0.39 | $-0.47 | -20.5% | ✗ MISS |
Q3 2022 | Jul 15, 2022 | $-0.50 | $-0.54 | -8.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.63 | $-0.58 | +7.9% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.84 | $-0.31 | +63.0% | ✓ BEAT |
Q4 2021 | Nov 24, 2021 | $-0.59 | $-1.08 | -83.1% | ✗ MISS |
Q2 2021 | Jun 16, 2021 | $-0.15 | $-0.27 | -80.0% | ✗ MISS |
Q2 2021 | Apr 15, 2021 | $-0.08 | $0.18 | +325.0% | ✓ BEAT |
Q1 2021 | Mar 31, 2021 | — | $-0.26 | — | — |
Q4 2020 | Dec 16, 2020 | $-0.33 | $-0.32 | +3.0% | ✓ BEAT |
Q2 2020 | Jun 15, 2020 | $-0.38 | $-0.47 | -23.7% | ✗ MISS |
Q2 2020 | Apr 23, 2020 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q1 2020 | Mar 31, 2020 | — | $-0.47 | — | — |
Q4 2019 | Dec 5, 2019 | $-19.13 | $-14.45 | +24.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about CNTG
What is CNTG's current stock price?
What is the analyst price target for CNTG?
What sector is Centogene N.V. in?
What is CNTG's market cap?
Does CNTG pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CNTG for comparison